Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen

This publication has 24 references indexed in Scilit:

• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication
  Hepatology, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001
• Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA
  Hepatology, 2000
• Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?
  Hepatology, 2000
• HEPATITIS C VIRAL DYNAMICS
  Clinics in Liver Disease, 1999
• EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999
  Journal of Hepatology, 1999
• Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
  New England Journal of Medicine, 1998
• Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
  Published by Elsevier ,1998
• Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C
  Hepatology, 1995